Vancouver, BC, Las Vegas, NV – April 30, 2024 (CSE: OVAT | OTCQB: OVATF) – Ovation Science Inc. (“Ovation” or the “Company”), with its proprietary topical and transdermal cannabis products powered by its patented skin delivery technology Invisicare®, today announced the official launch of its topical product line in Nevada with Planet 13 Holdings, Inc. (CSE: PLTH | OTCQX: PLNH)  (“Planet 13”). These products will be available in store, reach customers through wholesale channels and the hemp derived products will be available online, marking an exciting expansion of Planet 13’s product offerings. The cannabis derived topicals will be manufactured at the Planet 13 SuperStore in the state-of-the-art production facility where visitors can watch products being made, further enhancing the immersive customer experience that Planet 13 is renowned for. Planet 13’s 112,000 square foot SuperStore and entertainment complex is located just off The Strip in Las Vegas. Planet 13 accounts for approximately 9-percent of the cannabis retail market share for the entire state of Nevada.

“The launch of our topical products with Planet 13 in Nevada is exciting for the Company,” said Terry Howlett, President of Ovation. “Our products have always sold extremely well in Nevada; holding the position of #1 Topical for many years.”  He added, “Planet 13 has had extensive success in the past selling our topicals, but this time with the added incentive of launching the four products under their own brand. We know consumers will also be excited to see these topicals available throughout Nevada and in turn this will generate maximum revenue for Ovation and value for our shareholders.”

“We’ve experienced great success with our topical offerings both in-store and online. Introducing a MEDIZIN branded topical line perfectly aligns with our strategic goals in Nevada, allowing us to leverage our production facility to expand our brand presence and boost wholesale revenue,” explained Bob Groesbeck, Co-CEO of Planet 13. “We’re thrilled to secure the Nevada rights to Ovation Science’s patented technology and to harness the strength of our beloved MEDIZIN brand to dominate a new product category. This endeavor marks a significant stride towards optimizing our production facility, driving revenue growth, and enhancing our gross margins.”

The Planet 13 Topical Product Line Includes:

MEDIZIN REST:

3:1 Ratio – 375mg CBD & 125mg THC – A CBD-infused transdermal cream crafted to alleviate soreness and discomfort to foster relaxation for a restful night’s sleep.

MEDIZIN RECOVERY:

1:1 Ratio – 250mg CBD & 250mg THC – An ideal blend of CBD and THC to unlock the combined benefits of both cannabinoids to conjure the entourage effect

MEDIZIN RELIEF:

1:10 Ratio – 50mg CBD & 500mg THC – A THC-dominant transdermal cream designed to provide relief, complemented by CBD to balance the effects.

PLANET 13 PURE CBD:

Planet 13 PURE CBD with 400mg CBD per jar. A transdermal CBD cream designed to provide relief and promote relaxation.

Ovation leverages its expertise in the pharmaceutical industry by using its patented skin delivery technology Invisicare® in its highly effective, proprietary products. Invisicare, backed by over 20 years of research and development, enables substantially more CBD and THC and other cannabinoids to be delivered to and through the skin, which translates into better results for patients. In a recent in-house study, Ovation compared five CBD brand leaders to Ovation Science’s topical CBD cream. All competitor creams tested release less than 2% CBD compared to 40% release from Ovation Science products.

Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

About Planet 13

Planet 13 (https://planet13.com/investors/) is a vertically integrated cannabis company, with award-winning cultivation, production and dispensary operations across its locations in California, Nevada, Illinois, and upcoming sites in Florida. Home to the nation’s largest dispensary located just off The Strip in Las Vegas, Planet 13 continues to expand its footprint. With the recent debut of its first consumption lounge in Las Vegas, DAZED!, and the opening of its first Illinois dispensary in Waukegan, bringing unparalleled cannabis experiences to the Chicago metro area. Planet 13 holds a medical marijuana treatment center license in Florida allowing for state-wide expansion throughout the Sunshine State. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and innovative cannabis products. Licensed cannabis activity is legal in the states Planet 13 operates in but remains illegal under U.S. federal law. Planet 13’s shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and are quoted on the OTCQX under the symbol PLNH.

About Ovation Science Inc.

Ovation Science Inc. and its wholly-owned subsidiary; Ovation Science USA Inc., is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation’s own brands; ARLO CBD Beauty and InVibe® MD (“wellness” line); all powered by its patented Invisicare® skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation’s management and science team have created a unique pipeline of over thirty proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees’ sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.

Stock symbols:  CSE: OVAT and OTCQB: OVATF

Websites:

CORPORATE:  www.ovationscience.com

WELLNESS: www.invibemd.com

BEAUTY: www.arlocbdbeauty.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of sales and acceptance of its products in any of the state or country cited, continued sales in dispensaries or in retail markets or expansion to other states or countries. There are no guarantees of future performance or changes to regulations. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.

Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

CORPORATE INQUIRIES:

Doreen McMorran: info@ovationscience.com  PH:  604-982-5700

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

For immediate release. Vancouver, British Columbia, April 22, 2024: Cannabix Technologies Inc.(CSE: BLO, OTC PINK CURRENT: BLOZF)  (Frankfurt: 8CT) (the “Company”)  developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it will be presenting at the International Association for Chemical Testing (IACT) conference in April.  Cannabix’s Dr. Bruce Goldberger Ph.D., will be presenting on Science & Technology Behind Cannabis Breath Testing and the Company’s marijuana breathalyzer system at the conference workshop session. IACT is composed of governmental agency personnel involved in chemical testing related to traffic safety. IACT members are scientific and criminal justice professionals, including forensic scientists, regulatory inspectors, and law enforcement personnel with representatives from a majority of states and international members. IACT has standing committees to address various areas including legislation, training, new equipment and procedures and manufacturers of breath testing equipment.

The Cannabis Breath Testing workshop at IACT 2024 is designed to provide background information regarding the pharmacokinetics and pharmacodynamics of cannabinoids in breath, present the current technology for collection devices from commercial vendors, and discuss the necessary laboratory workflows and analytical considerations when testing these samples.

Dr. Bruce Goldberger is a professor and the former Chief of the Forensic Medicine Division in the Department of Pathology, Immunology and Laboratory Medicine in the College of Medicine at the University of Florida. Dr. Goldberger served as Director of the University of Florida forensic toxicology laboratory for 30 years. Dr. Goldberger is the Principal Investigator of the Florida Drug-Related Outcomes  Surveillance and Tracking System and Co-investigator of the National Drug Early Warning System. Dr. Goldberger is a consultant for the Centers for Disease Control and Prevention’s National Center for Injury Prevention and Control, Overdose Mortality Team, and the National Center for Health Statistics, Division of Vital Statistics. Dr. Goldberger is a consultant and senior advisor to Cannabix Technologies Inc.

About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of Breath Logix Series of autonomous breath alcohol detection devices for employers and a range of other settings.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact us by visiting https://cannabixtechnologies.com/contact/contact-us/ 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of breathalyzer technologies will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. The is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies. There is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities.  The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact
For additional information on Cannabix Technologies Inc. please visit our website at https://cannabixtechnologies.com/contact/contact-us/ 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

In the rapidly evolving cannabis industry, there are few platforms for brands to display their products and services in a professional format. Flower Expo, taking place in Massachusetts and Michigan this year, stands out as a beacon of innovation and connection. Flower Expo is the Premier B2B Cannabis Trade Show where brands meet buyers. This unique event is not just a trade show; it’s a movement towards creating a more efficient, high-vibe platform for the cannabis economy.

Flower Expo’s 2024 events, which include Massachusetts on June 5-6 and Michigan on August 7-8, will draw out some of the highest profile names in cannabis. Flower Expo is set to be one of the most important events for top brands and retailers while maintaining the perfect balance of business and culture. 

Flower Expo Massachusetts is set to host more than 150 brands in 2024, including Cresco Labs, PAX, Fernway, Select, Green Thumb Industries, Holistic Industries, Kanha, Nova Farms, and MariMed.

Also set to attend are the purchasing groups from more than 250 Massachusetts retailers, such as Theory Wellness, Rev Clinics, Bud’s Goods & Provisions, Insa, Garden Remedies, and Resinate.

For the Michigan event’s inaugural year, brands such as Bloom, NOBO, Cloud Cover, Glorious Cannabis, Lion Labs, and Pro Gro are set to exhibit, with top retailers Lume Cannabis, High Profile, Joyology, GAGE, Exclusive, and many others set to attend.

Photo Download: https://drive.google.com/file/d/1pOZ1L_-QqlZA85CgcBAFsdeeZFhwFdIR/view?usp=sharing

Jason Bello, founder of the event grew up in Las Vegas, NV, where his father climbed the corporate ladder beginning with the infamous computer trade show COMDEX until its 1996 acquisition, then transitioning to the Las Vegas Sands Corporation, which boasts the largest private convention center in the US, where he opened world renowned hotels in Vegas, Macau, and Singapore. His father was also a founding partner of Hall of Flowers, a California-based cannabis trade show, the event where Bello also got his start in the event business. Following his time at Hall of Flowers, Bello led sales at Source Cannabis and Green Street Festival prior to launching Flower Expo in 2023.

The success of Flower Expo lies in its unique approach to business events. While the show curates the perfect cast of attendees made up of top brands and retail decision makers, its focus on creating an authentic cannabis event with consumption and sampling sets it apart from the field. “What’s a cannabis event without the cannabis?” said Kai Brady, Flower Expo’s Director of Business Development. 

Flower Expo’s fixation on top brands and vetted buyers creates the most ideal sales and marketing opportunity for budding brands to expose purchasing decision makers to their products, packaging, brand values, team members, and culture. “It’s like the biggest farmer’s market you’ve ever been to,” Bello said, “And it’s incredibly important in any industry to procure products with a focus on the consumer — who they are, and what they like.”

After its blockbuster 2023 Massachusetts event, which brought out upwards of 70% of the state’s dispensaries and over 150 of the hottest brands, Flower Expo is set to launch the second iteration of its Massachusetts event on June 5-6, 2024. Additionally, a brand new event is scheduled in Michigan on August 7-8, 2024, set to shake up the Midwestern market. Flower Expo plans to continue its expansion to offer its superior platform to cannabis brands around the country.

About Flower Expo:

At Flower Expo, our mission is to connect and transform the cannabis industry through a professional, high-vibe, and efficient platform. We foster meaningful connections, strategic partnerships, and knowledge exchange to propel the industry forward. With a focus on professionalism, positive energy, and streamlined processes, we empower businesses and individuals to showcase their offerings, inspire innovation, and shape the future of cannabis.

Contact:

ops@theflowerexpo.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Experience “420 Daze” Promotions, Along With Deep Discounts on Cannabis Products at All High Profile Dispensary Locations Starting April 13th and Continuing Through April 21st

Cannabis Consumers From Each Dispensary Location Can Enter for a Chance to Win a $400 Live Nation Gift Card; Enjoy Live Music and Food Trucks on Site on Saturday, April 20th

ANN ARBOR, Mich., April 17, 2024 /PRNewswire/ — C3 Industries (“C3” or “the Company,”) a leading multi-state cannabis company dedicated to crafting premium cannabis experiences for consumers, is set to launch 420 celebrations at its High Profile dispensaries – commencing on Saturday, April 13, and concluding on Sunday, April 21. The theme for this event is “420 Daze – It’s High Time for Good Vibes,” featuring exciting offerings such as a $400 Live Nation concert giveaways, significant discounts on cannabis products, various in-store promotions and giveaways, as well as live music and food trucks on-site at select High Profile dispensaries located in Illinois, Michigan, Missouri, Massachusetts and New Jersey.

“The launch of our ‘420 Daze’ festivities at our High Profile dispensaries celebrate the iconic holiday of 420,” said C3 Industries Vice President of Marketing Scott Franco. “We look forward to celebrating with our local communities and serving up great fun, live music, killer deals and good vibes.”

420 Daze Summer Concert Series Contest: From April 13 to April 21, two fortunate winners in each High Profile market will receive a grand prize package. This includes two concert tickets presented as a Live Nation Digital Gift Card valued at $400, along with exclusive 420 Daze swag such as a limited-edition lawn chair, T-shirt, bucket hat, color-changing cup, lighter, rolling papers, air fresheners and stickers. To enter, simply visit your local High Profile shop to submit an in-store raffle, or follow your local High Profile Instagram account, which can be found via the High Profile Official page. Contestants can expect one winner from the in-store raffle and one from the social media raffle for each respective market. Additionally, High Roller Loyalty members with the highest number of visits during the 420 Daze promotions period will automatically be entered into the giveaway. The winners will be announced via High Profile’s Instagram page on Tuesday, 4/23, and will be contacted directly to provide shipping details.

420 Daze Deep Discounts and Events: Starting on Saturday, April 13 and through Sunday, April 21, each High Profile store location will kick off its 420 Daze celebrations with aggressive cannabis discounts, bundles and promotions such as doorbusters, buy one get one free (BOGO) and products priced at $0.01. Each day will feature different vendor-sponsored deals and deep discounts. Various High Profile dispensary locations will also host special events on 420 – Saturday, April 20th – featuring local musicians and food trucks, free meals for High Profile customers and other specials and giveaways [please see below for more details].

High Profile Michigan Locations
High Profile Ironwood: From 1 to 3 p.m., High Profile customers and cannabis fans can enjoy the solo performances of guitarist and singer Mike LaBo, followed by Marty E. from 3 to 5 p.m. Wow Weeniez on Wheelz will be serving food from 12 to 5 p.m. The first 50 customers presenting a High Profile receipt will receive a complimentary meal valued up to $10.

High Profile Buchanan: Solo guitarist and singer Abbigale Rose will perform from 1 to 5 p.m. Tony’s Kitchen will be serving food from 12 to 5 p.m. The first 50 customers with a High Profile receipt can enjoy a free meal valued up to $10.

High Profile Grand Rapids (Leonard St): The Duo Smokin Dobroles will entertain from 1 to 5 p.m. PizzaMI will be on-site from 12 to 5 p.m. with the first 50 customers presenting a High Profile receipt enjoying a free meal valued up to $15.

High Profile Missouri Locations
High Profile Cape Girardeau Dispensary: This location will have live music from 1 to 5 p.m. featuring Alex Reyna, a talented guitarist and singer performing as a duo. From 12 to 5 p.m., customers can grab a bite from Mudcat Mobile with the first 50 customers presenting a High Profile receipt receiving a complimentary meal valued up to $14.

High Profile Saint Charles Dispensary: Will have live musical duo led by Sean Canan’s Voodoo Players from 1 to 5 p.m.; and from 12 to 5 p.m. participants can indulge in Finger Lickin Good’s offerings. The first 50 customers with a High Profile receipt can savor a free meal, valued up to $14.

High Profile Saint Robert Dispensary: Will have live music from 1 to 5 p.m. by Riley Holtz, a skilled guitarist and singer; and JJ’s Wings N Things from 12 to 5 p.m. with the first 50 customers presenting a High Profile receipt receiving a meal for free valued up to $15.

High Profile West Plains Dispensary: Groove to the sounds of Mister Blackcat, a dynamic duo featuring bass and guitar from 1 to 5 p.m. and from 12 to 5 p.m. customers can satisfy their cravings with Mandy’s Hot Dogs. The first 50 customers showing a High Profile receipt receive a complimentary meal valued up to $10.

High Profile New Jersey Locations
High Profile Lakehurst: On Saturday, April 20, Duo Jammin Steel Drum Band will play from 1 to 5 p.m.; and Good Shore Eats will be on site from 12 to 5 p.m. Additionally, the first 50 customers with a High Profile receipt will receive a free meal valued up to $12.

High Profile Illinois Locations

High Profile Springfield: Starting at 8:30 a.m., indulge in complimentary Mel-o-Cream Donuts & Coffee on Saturday, April 20th (available while supplies last). Then in the afternoon, customers can enjoy the soulful melodies of solo pianist, Louis Pettinelli, from 1 to 5 p.m.

High Profile Massachusetts Locations
High Profile x Budega Dorchester Dispensary: From 1 to 5 p.m., groove to the tunes of the Birch Swart Duo. From 12 to 5 p.m., indulge in delicious offerings from the NAC Food Truck. The first 50 customers presenting a High Profile receipt can enjoy a complimentary meal valued up to $21.

About C3 Industries
C3 Industries is a multi-state, vertically integrated cannabis company headquartered in Ann Arbor, Michigan, with multiple product brands including the award-winning Cloud Cover Cannabis and Galactic Cannabis, and a retail network, High Profile Cannabis Shop. The company retails high-quality cannabis products at its High Profile locations in Michigan, Missouri, Massachusetts, Illinois and New Jersey. Additional High Profile retail locations are scheduled to open throughout 2024 in New Jersey, Illinois, Missouri and Connecticut. C3 currently operates almost 220,000 sq. ft. of total cultivation and processing facilities, with 125,000 sq. ft in Michigan, 37,000 sq. ft. in Massachusetts, 55,000 sq. ft. in Missouri. The company also has a 55,000 sq. ft. expansion nearing completion in Missouri and a 58,000 sq. ft. Connecticut facility in development.

For more information, visit www.c3industries.com. Additional information about High Profile Cannabis Shop can be found by signing up for the company’s newsletters at www.highprofilecannabis.com and on Instagram at @highprofileofficial_. Additional information on Cloud Cover Cannabis can be found at www.cloudcovercannabis.com and @cloudcovercannabis on Instagram. Additional information on Galactic Cannabis can be found at www.galacticcannabis.com and @galactic.cannabis on Instagram

SOURCE C3 Industries

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• The proposed acquisition of Siam Ventures, which provides contract manufacturing services through a subsidiary, will act as a gateway to large Asian markets for PharmaCielo product.
• Experienced investor, businessman and lawyer Louis Desmarais, the current Chairman and CEO of Siam Ventures, will join the Company’s board of directors on closing.

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

All amounts expressed in Canadian dollars unless otherwise noted

Toronto, Ontario and Rionegro, Colombia–(Newsfile Corp. – April 10, 2024) – PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) (“PharmaCielo” or the “Company”), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that it has signed a binding Letter of Intent to enter a proposed transaction (the “Proposed Acquisition”) whereby it would acquire 100% of the issued and outstanding shares of Siam Ventures Corporation (“Siam Ventures”) in exchange for common shares of PharmaCielo (the “PharmaCielo Shares”), representing aggregate consideration value of $3,000,000 (the “Purchase Price”). The Purchase Price shall be payable on closing of the Proposed Acquisition by way of the issuance of 13,636,363 PharmaCielo Shares to the shareholders of Siam Ventures on a pro rata basis, representing the equivalent of $3,000,000 (the “Consideration Shares”). The number of Consideration Shares to be issued have been determined based on a price of $0.22 per Consideration Share, which is equal to the volume weighted average price of the PharmaCielo Shares traded on the TSX Venture Exchange (“TSXV”) for the twenty (20) trading days immediately preceding today. Completion of the Proposed Acquisition is subject to due diligence, regulatory approvals, and the satisfaction of other customary closing conditions.

PharmaCielo also announced that it is undertaking a non-brokered private placement of 9,090,909 units (“Units”) at a price of $0.22 per Unit (the “Offering Price”), under the Listed Issuer Financing Exemption (“LIFE”). Certain insiders of PharmaCielo and existing investors of Siam Ventures plan to participate in the Offering. Each Unit will be comprised of (i) one common share (a “Common Share”) of the Company and (ii) one Common Share purchase warrant (a “Warrant”) of the Company (the “Offering”), for gross proceeds of $2.0 million. The Company has the option to increase the size of the Offering to $3.0 million, or an additional 4,545,455 Units. Each Warrant entitles the holder thereof to purchase one Common Share (a “Warrant Share”) at a price of $0.30 for a period of 24 months. Closing of the Offering may take place in one or more tranches, provided that the final tranche closing will occur no later than May 25, 2024, being 45 days following the date hereof (the “Closing Date”). The Company intends to use the net proceeds from the Offering to finance general working capital requirements, expand international markets, and to facilitate the production of product based on the current demand of its customers. Closing of the Offering is subject to regulatory approval including that of the TSX Venture Exchange (the “TSXV”). For additional terms of the Offering, refer to the section titled Additional Terms of the Offering in this press release.

Management Commentary

Marc Lustig, Chairman and CEO of PharmaCielo commented, “This proposed acquisition will provide PharmaCielo with a ready pipeline for its high-quality product as large Asian markets begin to open to cannabinoids. On closing, Louis Desmarais will join our board of directors. Mr. Desmarais is a uniquely qualified and accomplished professional with deep ties in these markets and we expect to benefit from his guidance.”

Mr. Lustig continued, “PharmaCielo’s management team has worked relentlessly over the past two years to drive efficiencies while building our sales pipeline. Our strategy is longer term in nature, based on early adoption in newly opening markets and integration into development-stage products. This strategy takes time to work, but it is about to start paying off. The recent announcement of Ease Labs’ contract with the State Government of São Paulo in Brazil, relying on our proprietary API, is just the beginning. I am personally one of the Company’s largest investors and am confident that this strategy will create enormous shareholder value as markets continue to open, and product development pipelines that are currently early stage, go commercial.”

Louis Desmarais, Chairman and CEO of Siam Ventures added, “Asia represents a very large, long-term opportunity for international cannabis producers. We have spent the past five years establishing the networks required to provide robust distribution across the continent as individual markets begin to open. We have chosen to join with PharmaCielo, and to invest our own capital alongside Marc and other insiders, because we believe that PharmaCielo has all the key attributes required for success in international markets – a deep shelf of high-quality products, a proprietary genetics bank, in-house pharma-level formulation expertise, low incremental cost to scale, and a structural cost advantage. Siam Ventures’ team brings a plug and play manufacturing and distribution platform in a region that we expect will become a much larger part of the global cannabis conversation over the next decade. We look forward to working with Marc and the team to capture this opportunity for PharmaCielo shareholders.”

Siam Ventures Corporation

Siam Ventures, and its principals with over 20 years of business experience in Thailand, have built enduring networks at the intersection of business, government and politics across Asia.

Louis Desmarais

Louis Desmarais is currently the Chairman & CEO of Siam Ventures. Mr. Desmarais is also the Honorary Consul General – Montreal, as well as an Honorary Trade Advisor, for the Royal Kingdom of Thailand.

Prior to Siam Ventures, Mr. Desmarais was the Managing Partner of Darwin Financial Corporation and the founder and managing partner of St-Lawrence Capital, LP, an early-stage venture capital fund, whose main investors included The Caisse de Dépôt et Placement du Québec, the Quebec Solidarity Fund and Investment Quebec. Before that, he was a general partner of Skypoint Capital Corporation, where he led Skypoint’s fundraising efforts and ran the fund’s Quebec operations. Prior to this, he was a partner of Wynnchurch Capital, a $500 million private equity firm based in Chicago and Montreal, where he played a key role in fund raising, and sourcing and monitoring the fund’s early-stage ventures. Between 1987 and 1999, Mr. Desmarais managed Desmarais Capital Corporation.

Mr. Desmarais began his career as a Chartered Accountant at Deloitte & Touche, following which he studied law. In 1985, he was the law clerk for the Chief Judge of the Tax Court of Canada, following which he was the law clerk for Justice Jean Beetz at the Supreme Court of Canada. In 1986, he joined the law firm of McCarthy Tétrault as a securities lawyer.

Additional Terms of the Offering

The Offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 Prospectus Exemptions and therefore the securities issued in the Offering will not be subject to a hold period in accordance with applicable Canadian securities laws. There is an offering document (the “Offering Document “) related to the Offering that can be accessed under the Company’s profile at www.sedarplus.ca and at www.pharmacielo.com. Prospective investors should read the Offering Document before making an investment decision.

In connection with the Offering, the Company will pay a commission or finder’s fee to eligible persons from the gross proceeds raised under the Offering. The Units will be offered by way of private placement in Ontario and such other provinces and territories of Canada and may be offered in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the “US Securities Act”), and applicable state securities laws, and certain other jurisdictions outside of Canada and the United States. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Units in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Units, Common Shares, Warrants and Warrant Shares issuable thereunder have not been, nor will they be, registered under the US Securities Act and such securities may not be offered or sold within the United States, or to or for the account or benefit of U.S. persons, absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements. This press release does not constitute an offer of Units, Common Shares and Warrants for sale, nor a solicitation for offers to buy such securities.

Financial and Legal Advisors

Bennet Jones LLP has acted as legal counsel and Cormark Securities Inc. as financial advisor for the Proposed Acquisition and Offering.

Grant of Stock Options, Restricted and Deferred Share Units

Effective April 9, 2024, PharmaCielo granted an aggregate of 3,050,000 stock options, 300,000 Deferred Share Units (“DSUs”), and 1,060,000 Restricted Share Units (“RSUs”) to directors, officers, and key employees. The Company also issued 1,545,948 DSUs to settle $340,109 director fees owed. The options and RSUs vest 50% immediately, 25% on the first-year anniversary and 25% on the second-year anniversary. The options are exercisable at $0.22 per share and expire five years from the date of grant. The RSUs, DSUs and options are granted pursuant to the Company’s RSU, DSU and stock option plans, respectively.

Shares for Settlement of Certain Amounts Owing

Today, the Company announced that as approved by TSXV, it issued 639,439 common shares of the Company (“Settlement Shares”), in satisfaction of $134,077 debt owed to certain former service providers of the Company.

The Company also announced that it intends to further issue, subject to the approval of TSXV, up to 1,323,960 Settlement Shares, in satisfaction of $291,270 debt owed to certain service providers of the Company. The deemed price of the common shares to be issued have been determined as C$0.22, being the 20-day Volume Weighted Average Price on the date the board of directors of the Corporation approved issuance of shares, (the “Deemed Price”). The Settlement Shares will be subject to a four-month hold period under applicable Canadian securities laws, starting from the date of issuance of the Settlement Shares.

About PharmaCielo

PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, pharmaceutical-grade medical cannabis products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro, Colombia.

The board of directors and executive team of PharmaCielo are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location plays in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

For further information:

Ian D. Atacan, Director & Chief Financial Officer
+1 (416) 562-3220
i.atacan@pharmacielo.com

Media and Investor Inquires:
investors@pharmacielo.com

Forward-Looking Statements

This news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as “expects”, “is expected”, “intends”, “anticipates”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may” or “will” be taken, occur or be completed or achieved.

Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including changes to PharmaCielo’s development plans, the failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of these products into other countries, TSX Venture Exchange approval, the inability to export or distribute commercial products through sales channels as anticipated due to economic or operational circumstances, risks associated with operating in Colombia, fluctuation of the market price for the Company’s products, risks associated with global economic instability relating to COVID-19 or other developments, risks related to retention of key Company personnel, currency exchange risk, competition in PharmaCielo’s market and other risks discussed or referred to under the heading “Risk Factors” in PharmaCielo’s Annual Information Form for the financial year 2019, and the Management’s Discussion and Analysis for the financial year 2022 which are both available at www.sedar.com. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Chicago, Ill., April 8, 2024 – Chicago Atlantic has deployed a $20 million facility in senior secured financing to Nova Farms, a fully integrated cannabis operator managing a Massachusetts cultivation farm, seven retail brands, and five full-service dispensaries across Massachusetts, Maine, and New Jersey.

Chicago Atlantic’s capital investment will support Nova Farms’ efforts to expand its footprint of dispensaries in key states, including New Jersey, a burgeoning market that has earned more than $1.3 billion since the beginning of adult-use cannabis sales in April 20221, and Connecticut, which legalized adult-use cannabis in January 2023 and saw $274 million in revenue in its first year2.

Nova Farms was among the first to secure licenses in Massachusetts upon the state’s legalization of adult-use cannabis back in 2016. Its new openings to date have shown a consistent track record of growth and profitability. This trajectory solidifies Nova Farms’ rising prominence in the cannabis industry, positioning the company for unparalleled success in the evolving market.

“Nova Farms has demonstrated its ability to operate successfully and identify attractive opportunities to accelerate its progress. We have every confidence in their plans to open additional locations across the Northeast, which will support their mission to increase safe and positive accessibility,” said Peter Sack, Partner at Chicago Atlantic.

With the legal U.S. cannabis industry expected to reach nearly $40 billion in 20243, Nova Farms and other multi-state operators are experiencing increased demand for high-quality retail products and convenient points of purchase. As Nova Farms continues to meet this demand, they invite equity investors to join them in their journey of expansion and innovation.

“Our partnership with Chicago Atlantic marks a new chapter in our longstanding contributions to the industry. We are extremely proud of our ability to control quality and efficiency in each element of our supply chain. It’s an honor to have a financial partner who believes in our integrated approach working directly with our team to chart a roadmap for realizing our goals,” said Derek Ross, CEO of Nova Farms. This collaboration not only accelerates Nova Farms’ strategic plans but also ensures its competitive edge as a leader in the cannabis market.

The next Nova Farms retail opening is planned for late 2024. This expansion reflects Nova’s commitment to enhancing accessibility to quality cannabis products and reinforces their vision for a future where Nova Farms is synonymous with excellence in the cannabis industry. For those interested in contributing to Nova’s growth, please contact Blair Fish, COO, for more details.

1 NJ.gov, March 2024.

2 NBC Connecticut, December 2023.

3 Statista Market Insights, April 2024.

About Chicago Atlantic

Chicago Atlantic is a private market investment manager focused on alternative industries and companies where demand for capital exceeds traditional supply. Founding Partners John Mazarakis, Tony Cappell and Andreas Bodmeier established Chicago Atlantic in 2019 to provide capital solutions to

state-licensed cannabis operators. The firm’s private investment strategies have grown to include opportunistic credit, private equity and impact investing with focuses on loans to esoteric industries, specialty asset-based loans, liquidity solutions and growth and technology finance. Chicago Atlantic has made over $2 billion in credit and equity investments to date. Chicago Atlantic’s team of over 75 professionals has offices in Miami, Florida and Chicago, Illinois. For more information on Chicago Atlantic’s financing products, visit chicagoatlantic.com.

About Nova Farms

Nova Farms was established by a group of cannabis entrepreneurs which burgeoned into an organized group of industry pioneers. The business began with several licenses and a farm in Massachusetts, and currently includes adult-use cannabis retail brands and full-service dispensaries in Massachusetts (Attleboro, Dracut and Framingham), Greenville, Maine and Woodbury, New Jersey. For more information, visit NovaFarms.com.

Press Contact

Alise M. Edgcomb

Managing Director, Public Relations

(419) 202 – 3988

aedgcomb@chicagoatlantic.com

Derek Ross

CEO, Nova Farms

(508) 212 – 4490

derek@novafarms.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

New Product Channel Expands & Accelerates 2024 Revenues

COSTA MESA, Calif., April 04, 2024 (GLOBE NEWSWIRE) — Rodedawg International Industries, Inc. (OTC: RWGI) proudly announces the Company, through our wholly owned subsidiary, Parabola Mgmt. LLC, has accelerated sales of hemp and cannabis derived isolates.

Chris Swartz, CEO, states: “We are proud to announce that last quarter management invested over six figures in developing a manufacturing facility for extraction of cannabis derived isolates from hemp. The internal investment by our leadership is specifically for one of our largest revenue centers which benefits all Rodedawg shareholders. We passionately believe that as the leadership of the company we should demonstrate with our own dollars the value of the Rodedawg expansion for 2024 and beyond. We have completed the initial test of the equipment, and the Company is now at 65% production of the cannabis derivatives and isolates, and our revenues are growing rapidly.”

Mr. Swartz adds, “According to Zion Market Research, the Global Cannabis Extract Market is growing at CAGR of 16.8% and expected to reach 21.6 Billion by 2026. This is a major milestone for our Rodedawg shareholders as we now have in place our own manufacturing capability, our own distribution, and our own sales channels. Rather than grow from a secondary market, it is particularly important that we are growing from the #1 cannabis market in the world. In the coming quarters we have planned expansion into additional states bringing Rodedawg into the MSO (multi-state operator) category.”

Mr. Swartz concludes, “Quite frankly, it has been a multi-year journey for our shareholders during which we have been building the company’s infrastructure for the current growth we are now experiencing. We truly are honored and proud to be reporting the upcoming Disclosure. We believe that this period of growth is the reflection of the combined determination of our team and shareholders to have Rodedawg becoming a dominant force in the #1 cannabis market in the world. These preliminary sales that will be reported in our first quarter Disclosure for 2024 will be the indicator of continued growth of the hemp derived isolates channel. We are working quickly to complete the Disclosure. The company continues to encourage our shareholders to re-visit our corporate roadmap and corporate video area on the website at https://www.BuddingHorizon.com. We are confident that our strategically planned roadmap of expansion via sales, acquisitions and mergers will increase 2024 revenues to meet and potentially exceed our stated goal of 7 million annually.”

About Rodedawg International Industries, Inc.

Rodedawg International Industries, Inc. (OTC: RWGI) is focused on providing management services, acquisitions and restructuring resources throughout the regulated California cannabis market. We are a trusted partner and asset to licensed cultivation, distributors, manufacturers, and retail dispensaries.

Please note the company’s Twitter address is: https://twitter.com/RWGImerger for regular updates.

About Budding Horizon, LLC

Budding Horizon, LLC is a California Limited Liability Company with offices in Orange County, California. The company is focused on providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.

The company website is: https://buddinghorizon.com/

About Brother Buds

Brother Buds is a cannabis delivery service based in Costa Mesa, California. During the month of July 2023, the Rodedawg will operate Brother Buds under a non-storefront cannabis delivery license. The cannabis delivery service will focus on Los Angeles County, Orange County, and norther San Diego County in the demographic area of 23.86 million in 2019. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.

The company website is: https://BrotherBuds.com

Make sure to follow us at: https://twitter.com/BrotherBudsOC

About Elixicure

Elixicure is a leading provider of manufacturing and capsule encapsulation services. We offer a wide range of services to meet the diverse needs of our clients, including capsule encapsulation, formulation, manufacturing, labeling and bottle filling. Our state-of-the-art facilities and experienced team of professionals allow us to deliver high-quality products and exceptional customer service. Whether you are looking for small-scale or large-scale production, we have the expertise and capabilities to meet your needs. Contact us today to learn more about how we can support your manufacturing and encapsulation needs.

The company website is: https://elixicure.com/

Make sure to follow us at: https://twitter.com/Elixicure

Contact Information:

Rodedawg International Industries, Inc.
1-800-793-0355
ir@buddinghorizon.com

Safe Harbor Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Rodedawg International Industries, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LAS VEGAS, NV, March 25, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — One World Products, Inc. (“OWP”) (OTCQB: OWPC), a trailblazer in hemp and cannabis production, proudly announces an exclusive agreement with Procepack Corp., the acclaimed global leader in packaging line and automated integration equipment. This agreement grants OWP the perpetual exclusive rights to purchase advanced PreRoll-Er fully automated pre-roll filler systems within Colombia, contingent on meeting production volume targets and future equipment acquisitions.

The PreRoll-Er 400 system is a testament to efficiency, capable of producing up to 2,200 pre-roll products per hour – that’s 17.6K daily, approximately 370K monthly, and over 4.5 million annually, with a complete packaging solution included. This marks a significant advancement in OWP’s production capabilities and positions the company to scale its operations to unprecedented levels.

Under the terms of the agreement, effective February 26, 2024, Procepack will support OWP’s expansion in the expanding global cannabis market by ensuring access to cutting-edge technology that streamlines the production process. Procepack, known for its robust portfolio of innovative machinery brings expertise in labelers, cappers, liquid fillers, and other complementary machines, all made in their Quebec factory.

Isiah Thomas, CEO and Chairman of One World Products, expressed his enthusiasm: “Partnering with PreRoll-Er represents a significant leap forward for OWP in our production technology. The model 400 system will dramatically enhance our efficiency and output, helping us keep pace with the growing demand for our products. This agreement not only demonstrates our mutual commitment but also solidifies OWP’s foothold as an industry powerhouse.”

Francis Bouchard, Marketing Director of PreRoll-Er, explained: “Partnering with OWP will help us open a brand-new market for our machines. As the world’s largest cannabis producer, Colombia is a very interesting market for us, and we’re excited to start this journey with a solid partner like One World Products.”

The pre-roll market has shown remarkable growth in both the US and Canada, a trend that is expected to reflect globally. As the third most popular cannabis product category in the US and the second in Canada, pre-rolls have seen a 13.4% growth in the US and a substantial 36.5% growth in Canada. This surge indicates a flourishing market with vast global potential, positioning OWP favorably in its strategic expansion to meet the rising international demand.

About Procepack Corp.

Procepack is a premier manufacturer and integrator, providing packaging solutions to the food, pharmaceutical, cosmetics, and chemical industries. With a commitment to excellence and growth, Procepack offers unmatched after-sales support and repurchase options for old machinery, reinforcing their clients’ development. PreRoll-Er is a trademark by Procepack Corp. for the cannabis industry.

For more information, please visit https://preroll-er.com/.

About One World Products, Inc. (OTCQB: OWPC)

One World Products is a fully licensed hemp and cannabis producer with offices in Las Vegas, Nevada, and offices and operations in Bogota and Popayan, Colombia. One World Products planted its first crop of cannabis in 2018 at its cultivation site in Popayan, Colombia, and began harvesting commercially in the first quarter of 2020.

For more information, please visit https://oneworldproducts.com/. #HempIsTheNewPlastic (TM)

Forward-Looking Statements:

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov.

All forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement was made, except to the extent required by applicable securities laws.

Investor Contact:

ClearThink IR
bloper@clearthink.capital
602-785-4120

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Standard Farms Dubbed Best Vape Cartridge in Massachusetts

PHOENIX, March 25, 2024 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (Cboe: TILT) (OTCQB: TLLTF), a global provider of cannabis business solutions including inhalation technologies, cultivation, manufacturing, processing, brand development and retail, announced today that its subsidiary Standard Farms won first place for best vape cartridge in the 2024 NECANN Cup with the Mimosa Liquid Live Rosin “All-in-One” Vape using the Jupiter/CCELL Voca Pro hardware.

“Being awarded the best vape product at one of the nation’s leading cannabis competitions with our sought-after Mimosa live rosin strain helps solidify TILT’s position as an industry leader in product and hardware innovation,” said Tim Conder, Chief Executive Officer of TILT. “Our team deserves recognition for their commitment to delivering the best cannabis products across the markets we serve.”

Standard Farms’ Voca Pro Liquid Live Rosin “All-In-One” Vape combines the functionality of a high-quality hardware device with the potency and efficacy of a solventless cannabis input material. The Voca Pro device, provided by Jupiter Research and powered by CCELL technologies, is calibrated to ensure the rosin is heated to the perfect temperature for optimal flavor and vapor production, guaranteeing a smooth and flavorful draw from the first inhale to the last.

Massachusetts patients and consumers can find Standard Farms products in-store at any of the Commonwealth Alternative Care, Inc. locations across the state or place an online order for pick-up or delivery at commonwealthaltcare.org.

Dispensaries interested in Standard Farms or any of our other brand partner portfolio products can contact our wholesale team at wholesale@tiltholdings.com.

About TILT
TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 40 states in the U.S., as well as Canada, Israel, South America and the European Union. TILT’s core businesses include Jupiter Research LLC, a wholly-owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations, Commonwealth Alternative Care, Inc. in Massachusetts, Standard Farms LLC in Pennsylvania, and Standard Farms Ohio, LLC in Ohio. TILT is headquartered in Phoenix, Arizona. For more information, visit www.tiltholdings.com.

Company Contact:
Lynn Ricci, VP of Investor Relations & Corporate Communications
TILT Holdings Inc.
lricci@tiltholdings.com

Media Contact:
Madison Mullis
Trailblaze
TILT@trailblaze.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LOS ANGELES, March 22, 2024 /PRNewswire/ —  Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a leader in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products, today announced the pricing of a public offering of 2,050,000 shares of common stock at a price of $6.00 per share for gross proceeds of $12,300,000, prior to deducting the placement agent fees and expected offering expenses payable by the Company. The closing of the offering is expected to take place on or about March 26, 2024, subject to the satisfaction or waiver of customary closing conditions.

Roth Capital Partners acted as the lead placement agent for the offering.  TFI Securities and Futures Limited acted as co-placement agent for the offering.

The Company intends to use the net proceeds of the offering in connection with the establishment and operation of its manufacturing facility in Malaysia, the funding of its joint venture with Touch Point Worldwide Inc. d/b/a Berify and Chemular Inc. if the definitive documentation contemplated by the previously announced amended term sheet and letter of intent is executed before the related drop dead date, and for working capital and general corporate purposes, including research and development.

The shares described above were offered pursuant to a registration statement on Form S-1 (File No. 333-276804), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on March 21, 2024. A final prospectus relating to the offering will be filed by the Company with the SEC. When available, copies of the final prospectus can be obtained at the SEC’s website at www.sec.gov or from Roth Capital Partners, LLC , 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660, (800) 678-9147.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor will there be any sales of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Ispire Technology Inc.

Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 200 patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on  Instagram, LinkedIn, Facebook, Twitter and YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the expected closing date of the public offering and the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements are subject to risk and uncertainties, including, but not limited to, market conditions, the ability of the Company to satisfy the conditions to the closing of the offering, and those described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” in the Registration Statement on Form S-1, as amended, initially filed with the SEC (Reg. No. 333-276804) on February 1, 2024 and any subsequent filings which Ispire makes with the U.S. Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the press release relate only to events or information as of the date on which the statements are made in the press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

Contact:
For more information, kindly contact:
Investor Relations
Sherry Zheng
718.213.7386
ir@ispiretechnology.com

Ellen Mellody
570-209-2947
EMellody@kcsa.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.